Buy Stock In Gw Pharmaceuticals -

: By acquiring GW, Jazz Pharmaceuticals significantly reduced its reliance on its flagship narcolepsy drug, Xyrem . The combined company now has a robust portfolio across neuroscience and oncology.

: The acquisition included GW’s cannabinoid product platform and clinical-stage programs for additional indications such as autism, schizophrenia, and multiple sclerosis-related spasticity. buy stock in gw pharmaceuticals

: Epidiolex was the first FDA-approved plant-derived cannabinoid medicine, used to treat severe forms of childhood-onset epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. It reached over $500 million in annual net sales in 2020 and has continued to expand globally as Epidyolex in Europe. In the months following the close, Jazz reported

Investment Rationale for GW Pharmaceuticals (via Jazz Pharmaceuticals) In the months following the close

: The deal was designed to accelerate double-digit revenue growth. In the months following the close, Jazz reported that newly acquired products like Epidiolex contributed significantly to its total net product sales. Considerations Before Buying

GW Pharmaceuticals pioneered the use of cannabis-derived medicines, most notably . Since the acquisition, this platform has become a cornerstone of the Jazz Pharmaceuticals business model.

To invest in the GW Pharmaceuticals portfolio today, you would need to buy shares of its parent company, .